Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights
Diabetes mellitus is a chronic and most prevalent metabolic disorder affecting 422 million the people worldwide and causing life‐threatening associated conditions including disorders of kidney, heart, and nervous system as well as leg amputation and retinopathy. Steadily rising cases from the last f...
Gespeichert in:
| Veröffentlicht in: | Chemistry & biodiversity 2024-09, Vol.21 (9), p.e202401109-n/a |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | n/a |
|---|---|
| container_issue | 9 |
| container_start_page | e202401109 |
| container_title | Chemistry & biodiversity |
| container_volume | 21 |
| creator | Singh, Atamjit Singh, Karanvir Sharma, Aman Kaur, Uttam Kaur, Kamaljit Mohinder Singh Bedi, Preet |
| description | Diabetes mellitus is a chronic and most prevalent metabolic disorder affecting 422 million the people worldwide and causing life‐threatening associated conditions including disorders of kidney, heart, and nervous system as well as leg amputation and retinopathy. Steadily rising cases from the last few decades suggest the failure of currently available drugs in containment of this disease. α‐Glucosidase is a potential target for effectively tackling this disease and attracting significant interest from medicinal chemists around the globe. Besides having a set of side effects, currently available α‐glucosidase inhibitors (carbohydrate mimics) offer better tolerability, safety, and synergistic pharmacological outcomes with other antidiabetic drugs therefore medicinal chemists have working extensively over last three decades for developing alternative α‐glucosidase inhibitors. The 1,2,3‐Triazole nucleus is energetically used by various research groups around the globe for the development of α‐glucosidase inhibitors posing it as an optimum scaffold in the field of antidiabetic drug development. This review is a systematic analysis of α‐glucosidase inhibitors developed by employing 1,2,3‐triazole scaffold with special focus on design strategies, structure‐activity relationships, and mechanism of inhibitory effect. This article will act as lantern for medicinal chemists in developing of potent, safer, and effective α‐glucosidase inhibitors with desired properties and improved therapeutic efficacy. |
| doi_str_mv | 10.1002/cbdv.202401109 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3074728465</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3117643525</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2589-7c5ecd036c81f2eba3d3d014f21683323c239bee2fc8e23ee27c74685f2f6a8a3</originalsourceid><addsrcrecordid>eNqFkc1uEzEUhS1UREth22VlqRsWSfDPjMfTXZpCqVSEVApby-O507ia2KntCQorHoElr8GL8BA8CY5SgtQNKx8dffeTpYPQESUTSgh7bZp2NWGEFYRSUj9BB1RQNqZSkr1drtg-eh7jXeZzL5-hfS7rktZCHKAf12DAJXwOK-j9cpFzxNZhOmIj_vvb95tg9VffAz7TEVr862fuLvrB-Gjb3OBLN7eNTT7E0-yI9tbhjynoBLcW4miTB5OGAPlsapJd2bTG19DrZL2Lc7vE2rX4PZi5djYma7IwS-YpvkBPO91HePnwHqJPb9_czN6Nrz5cXM6mV2PDSlmPK1OCaQkXRtKOQaN5y1tCi45RITln3DBeNwCsMxIYz6EyVSFk2bFOaKn5IXq19S6Dvx8gJrWw0UDfawd-iIqTqqiYLESZ0ZNH6J0fgsu_U5zSShS8ZBtqsqVM8DEG6NQy2IUOa0WJ2mymNpup3Wb54PhBOzQLaHf435EyUG-BL7aH9X90anZ2_vmf_A8n7Khh</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3117643525</pqid></control><display><type>article</type><title>Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights</title><source>MEDLINE</source><source>Wiley Online Library Journals</source><creator>Singh, Atamjit ; Singh, Karanvir ; Sharma, Aman ; Kaur, Uttam ; Kaur, Kamaljit ; Mohinder Singh Bedi, Preet</creator><creatorcontrib>Singh, Atamjit ; Singh, Karanvir ; Sharma, Aman ; Kaur, Uttam ; Kaur, Kamaljit ; Mohinder Singh Bedi, Preet</creatorcontrib><description>Diabetes mellitus is a chronic and most prevalent metabolic disorder affecting 422 million the people worldwide and causing life‐threatening associated conditions including disorders of kidney, heart, and nervous system as well as leg amputation and retinopathy. Steadily rising cases from the last few decades suggest the failure of currently available drugs in containment of this disease. α‐Glucosidase is a potential target for effectively tackling this disease and attracting significant interest from medicinal chemists around the globe. Besides having a set of side effects, currently available α‐glucosidase inhibitors (carbohydrate mimics) offer better tolerability, safety, and synergistic pharmacological outcomes with other antidiabetic drugs therefore medicinal chemists have working extensively over last three decades for developing alternative α‐glucosidase inhibitors. The 1,2,3‐Triazole nucleus is energetically used by various research groups around the globe for the development of α‐glucosidase inhibitors posing it as an optimum scaffold in the field of antidiabetic drug development. This review is a systematic analysis of α‐glucosidase inhibitors developed by employing 1,2,3‐triazole scaffold with special focus on design strategies, structure‐activity relationships, and mechanism of inhibitory effect. This article will act as lantern for medicinal chemists in developing of potent, safer, and effective α‐glucosidase inhibitors with desired properties and improved therapeutic efficacy.</description><identifier>ISSN: 1612-1872</identifier><identifier>ISSN: 1612-1880</identifier><identifier>EISSN: 1612-1880</identifier><identifier>DOI: 10.1002/cbdv.202401109</identifier><identifier>PMID: 38951966</identifier><language>eng</language><publisher>Switzerland: Wiley Subscription Services, Inc</publisher><subject>1,2,3-triazole ; alpha-Glucosidases - chemistry ; alpha-Glucosidases - metabolism ; Amputation ; Antidiabetic ; Antidiabetics ; Antifungal agents ; Carbohydrates ; Chemical activity ; Chemists ; Diabetes mellitus ; Drug Design ; Drug development ; Drugs ; Effectiveness ; Glucosidase ; Glycoside Hydrolase Inhibitors - chemical synthesis ; Glycoside Hydrolase Inhibitors - chemistry ; Glycoside Hydrolase Inhibitors - pharmacology ; Heart diseases ; Humans ; Hypoglycemic Agents - chemical synthesis ; Hypoglycemic Agents - chemistry ; Hypoglycemic Agents - pharmacology ; Inhibitors ; Metabolic disorders ; Molecular Structure ; Nervous system ; Postprandial hyperglycemia ; Renal failure ; Retinopathy ; Scaffolds ; Side effects ; Structure-Activity Relationship ; Triazoles ; Triazoles - chemical synthesis ; Triazoles - chemistry ; Triazoles - pharmacology ; α-Glucosidase</subject><ispartof>Chemistry & biodiversity, 2024-09, Vol.21 (9), p.e202401109-n/a</ispartof><rights>2024 Wiley-VHCA AG, Zurich, Switzerland</rights><rights>2024 Wiley-VHCA AG, Zurich, Switzerland.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2589-7c5ecd036c81f2eba3d3d014f21683323c239bee2fc8e23ee27c74685f2f6a8a3</cites><orcidid>0000-0001-5439-8032</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcbdv.202401109$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcbdv.202401109$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38951966$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Kamaljit</creatorcontrib><creatorcontrib>Mohinder Singh Bedi, Preet</creatorcontrib><title>Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights</title><title>Chemistry & biodiversity</title><addtitle>Chem Biodivers</addtitle><description>Diabetes mellitus is a chronic and most prevalent metabolic disorder affecting 422 million the people worldwide and causing life‐threatening associated conditions including disorders of kidney, heart, and nervous system as well as leg amputation and retinopathy. Steadily rising cases from the last few decades suggest the failure of currently available drugs in containment of this disease. α‐Glucosidase is a potential target for effectively tackling this disease and attracting significant interest from medicinal chemists around the globe. Besides having a set of side effects, currently available α‐glucosidase inhibitors (carbohydrate mimics) offer better tolerability, safety, and synergistic pharmacological outcomes with other antidiabetic drugs therefore medicinal chemists have working extensively over last three decades for developing alternative α‐glucosidase inhibitors. The 1,2,3‐Triazole nucleus is energetically used by various research groups around the globe for the development of α‐glucosidase inhibitors posing it as an optimum scaffold in the field of antidiabetic drug development. This review is a systematic analysis of α‐glucosidase inhibitors developed by employing 1,2,3‐triazole scaffold with special focus on design strategies, structure‐activity relationships, and mechanism of inhibitory effect. This article will act as lantern for medicinal chemists in developing of potent, safer, and effective α‐glucosidase inhibitors with desired properties and improved therapeutic efficacy.</description><subject>1,2,3-triazole</subject><subject>alpha-Glucosidases - chemistry</subject><subject>alpha-Glucosidases - metabolism</subject><subject>Amputation</subject><subject>Antidiabetic</subject><subject>Antidiabetics</subject><subject>Antifungal agents</subject><subject>Carbohydrates</subject><subject>Chemical activity</subject><subject>Chemists</subject><subject>Diabetes mellitus</subject><subject>Drug Design</subject><subject>Drug development</subject><subject>Drugs</subject><subject>Effectiveness</subject><subject>Glucosidase</subject><subject>Glycoside Hydrolase Inhibitors - chemical synthesis</subject><subject>Glycoside Hydrolase Inhibitors - chemistry</subject><subject>Glycoside Hydrolase Inhibitors - pharmacology</subject><subject>Heart diseases</subject><subject>Humans</subject><subject>Hypoglycemic Agents - chemical synthesis</subject><subject>Hypoglycemic Agents - chemistry</subject><subject>Hypoglycemic Agents - pharmacology</subject><subject>Inhibitors</subject><subject>Metabolic disorders</subject><subject>Molecular Structure</subject><subject>Nervous system</subject><subject>Postprandial hyperglycemia</subject><subject>Renal failure</subject><subject>Retinopathy</subject><subject>Scaffolds</subject><subject>Side effects</subject><subject>Structure-Activity Relationship</subject><subject>Triazoles</subject><subject>Triazoles - chemical synthesis</subject><subject>Triazoles - chemistry</subject><subject>Triazoles - pharmacology</subject><subject>α-Glucosidase</subject><issn>1612-1872</issn><issn>1612-1880</issn><issn>1612-1880</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1uEzEUhS1UREth22VlqRsWSfDPjMfTXZpCqVSEVApby-O507ia2KntCQorHoElr8GL8BA8CY5SgtQNKx8dffeTpYPQESUTSgh7bZp2NWGEFYRSUj9BB1RQNqZSkr1drtg-eh7jXeZzL5-hfS7rktZCHKAf12DAJXwOK-j9cpFzxNZhOmIj_vvb95tg9VffAz7TEVr862fuLvrB-Gjb3OBLN7eNTT7E0-yI9tbhjynoBLcW4miTB5OGAPlsapJd2bTG19DrZL2Lc7vE2rX4PZi5djYma7IwS-YpvkBPO91HePnwHqJPb9_czN6Nrz5cXM6mV2PDSlmPK1OCaQkXRtKOQaN5y1tCi45RITln3DBeNwCsMxIYz6EyVSFk2bFOaKn5IXq19S6Dvx8gJrWw0UDfawd-iIqTqqiYLESZ0ZNH6J0fgsu_U5zSShS8ZBtqsqVM8DEG6NQy2IUOa0WJ2mymNpup3Wb54PhBOzQLaHf435EyUG-BL7aH9X90anZ2_vmf_A8n7Khh</recordid><startdate>202409</startdate><enddate>202409</enddate><creator>Singh, Atamjit</creator><creator>Singh, Karanvir</creator><creator>Sharma, Aman</creator><creator>Kaur, Uttam</creator><creator>Kaur, Kamaljit</creator><creator>Mohinder Singh Bedi, Preet</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TM</scope><scope>8FD</scope><scope>FR3</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid></search><sort><creationdate>202409</creationdate><title>Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights</title><author>Singh, Atamjit ; Singh, Karanvir ; Sharma, Aman ; Kaur, Uttam ; Kaur, Kamaljit ; Mohinder Singh Bedi, Preet</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2589-7c5ecd036c81f2eba3d3d014f21683323c239bee2fc8e23ee27c74685f2f6a8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>1,2,3-triazole</topic><topic>alpha-Glucosidases - chemistry</topic><topic>alpha-Glucosidases - metabolism</topic><topic>Amputation</topic><topic>Antidiabetic</topic><topic>Antidiabetics</topic><topic>Antifungal agents</topic><topic>Carbohydrates</topic><topic>Chemical activity</topic><topic>Chemists</topic><topic>Diabetes mellitus</topic><topic>Drug Design</topic><topic>Drug development</topic><topic>Drugs</topic><topic>Effectiveness</topic><topic>Glucosidase</topic><topic>Glycoside Hydrolase Inhibitors - chemical synthesis</topic><topic>Glycoside Hydrolase Inhibitors - chemistry</topic><topic>Glycoside Hydrolase Inhibitors - pharmacology</topic><topic>Heart diseases</topic><topic>Humans</topic><topic>Hypoglycemic Agents - chemical synthesis</topic><topic>Hypoglycemic Agents - chemistry</topic><topic>Hypoglycemic Agents - pharmacology</topic><topic>Inhibitors</topic><topic>Metabolic disorders</topic><topic>Molecular Structure</topic><topic>Nervous system</topic><topic>Postprandial hyperglycemia</topic><topic>Renal failure</topic><topic>Retinopathy</topic><topic>Scaffolds</topic><topic>Side effects</topic><topic>Structure-Activity Relationship</topic><topic>Triazoles</topic><topic>Triazoles - chemical synthesis</topic><topic>Triazoles - chemistry</topic><topic>Triazoles - pharmacology</topic><topic>α-Glucosidase</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Atamjit</creatorcontrib><creatorcontrib>Singh, Karanvir</creatorcontrib><creatorcontrib>Sharma, Aman</creatorcontrib><creatorcontrib>Kaur, Uttam</creatorcontrib><creatorcontrib>Kaur, Kamaljit</creatorcontrib><creatorcontrib>Mohinder Singh Bedi, Preet</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Chemistry & biodiversity</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Atamjit</au><au>Singh, Karanvir</au><au>Sharma, Aman</au><au>Kaur, Uttam</au><au>Kaur, Kamaljit</au><au>Mohinder Singh Bedi, Preet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights</atitle><jtitle>Chemistry & biodiversity</jtitle><addtitle>Chem Biodivers</addtitle><date>2024-09</date><risdate>2024</risdate><volume>21</volume><issue>9</issue><spage>e202401109</spage><epage>n/a</epage><pages>e202401109-n/a</pages><issn>1612-1872</issn><issn>1612-1880</issn><eissn>1612-1880</eissn><abstract>Diabetes mellitus is a chronic and most prevalent metabolic disorder affecting 422 million the people worldwide and causing life‐threatening associated conditions including disorders of kidney, heart, and nervous system as well as leg amputation and retinopathy. Steadily rising cases from the last few decades suggest the failure of currently available drugs in containment of this disease. α‐Glucosidase is a potential target for effectively tackling this disease and attracting significant interest from medicinal chemists around the globe. Besides having a set of side effects, currently available α‐glucosidase inhibitors (carbohydrate mimics) offer better tolerability, safety, and synergistic pharmacological outcomes with other antidiabetic drugs therefore medicinal chemists have working extensively over last three decades for developing alternative α‐glucosidase inhibitors. The 1,2,3‐Triazole nucleus is energetically used by various research groups around the globe for the development of α‐glucosidase inhibitors posing it as an optimum scaffold in the field of antidiabetic drug development. This review is a systematic analysis of α‐glucosidase inhibitors developed by employing 1,2,3‐triazole scaffold with special focus on design strategies, structure‐activity relationships, and mechanism of inhibitory effect. This article will act as lantern for medicinal chemists in developing of potent, safer, and effective α‐glucosidase inhibitors with desired properties and improved therapeutic efficacy.</abstract><cop>Switzerland</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38951966</pmid><doi>10.1002/cbdv.202401109</doi><tpages>28</tpages><orcidid>https://orcid.org/0000-0001-5439-8032</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1612-1872 |
| ispartof | Chemistry & biodiversity, 2024-09, Vol.21 (9), p.e202401109-n/a |
| issn | 1612-1872 1612-1880 1612-1880 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3074728465 |
| source | MEDLINE; Wiley Online Library Journals |
| subjects | 1,2,3-triazole alpha-Glucosidases - chemistry alpha-Glucosidases - metabolism Amputation Antidiabetic Antidiabetics Antifungal agents Carbohydrates Chemical activity Chemists Diabetes mellitus Drug Design Drug development Drugs Effectiveness Glucosidase Glycoside Hydrolase Inhibitors - chemical synthesis Glycoside Hydrolase Inhibitors - chemistry Glycoside Hydrolase Inhibitors - pharmacology Heart diseases Humans Hypoglycemic Agents - chemical synthesis Hypoglycemic Agents - chemistry Hypoglycemic Agents - pharmacology Inhibitors Metabolic disorders Molecular Structure Nervous system Postprandial hyperglycemia Renal failure Retinopathy Scaffolds Side effects Structure-Activity Relationship Triazoles Triazoles - chemical synthesis Triazoles - chemistry Triazoles - pharmacology α-Glucosidase |
| title | Recent Developments in 1,2,3‐Triazole Based α‐Glucosidase Inhibitors: Design Strategies, Structure‐Activity Relationship and Mechanistic Insights |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T21%3A12%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Recent%20Developments%20in%201,2,3%E2%80%90Triazole%20Based%20%CE%B1%E2%80%90Glucosidase%20Inhibitors:%20Design%20Strategies,%20Structure%E2%80%90Activity%20Relationship%20and%20Mechanistic%20Insights&rft.jtitle=Chemistry%20&%20biodiversity&rft.au=Singh,%20Atamjit&rft.date=2024-09&rft.volume=21&rft.issue=9&rft.spage=e202401109&rft.epage=n/a&rft.pages=e202401109-n/a&rft.issn=1612-1872&rft.eissn=1612-1880&rft_id=info:doi/10.1002/cbdv.202401109&rft_dat=%3Cproquest_cross%3E3117643525%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3117643525&rft_id=info:pmid/38951966&rfr_iscdi=true |